tbuckley/cabot-search huggingface dataset:
Stereotactic bradiotherapy (SRT) for operable stage I non-small cell lung cancer: Is SRT comparable to surgery?
Authors: H. Onishi, H. Shirato, Y. Nagata, M. Hiraoka, G. Kotaro, K. Karasawa, Y. Niibe, K. Hayakawa, Y. Takai, T. Kimura
Journal: Journal of Clinical Oncology (2007)

7623 Background: Stereotactic radiotherapy (SRT) has been aggressively performed as a radical treatment for stage I non-small cell lung cancer (NSCLC) in Japan, however most cases were medically inoperable. In a large Japanese multi-institutional experience, we reviewed the treatment outcome of SRT for medically operable stage I NSCLC cases with the patients’ refusal to surgery. Methods: In 1995–2004, 86 medically operable patients with stage I NSCLC (median age, 74 years; 62 T1N0M0; 24 T2N0M0) were treated with SRT alone in 14 reliable institutions. Stereotactic three-dimensional treatment was performed using non-coplanar dynamic arcs or multiple static ports. A total dose of 20 to 72.5 Gy at the isocenter was administered in 1 to 10 fractions. Median calculated biological effective dose (BED) was 115 Gy (range, 100–153 Gy). The data was collected and analyzed in a retrospective manner. Results: During follow-up (median, 43 months), pulmonary complications of above grade 2 arose in 4 patients (5.8%). Local control rates at 3 and 5-year post SRT were 88.1% and 85.5%, respectively. Three and 5-year overall survival rates were 80.7% and 71.3%, respectively. Five-year overall survival rate for patients whose age was over 70 years (n=27) and under 70 years (n=58) were 74.3% and 69.6%, respectively. Five-year overall survival rate for stage IA (n=62) and IB (n=24) cases were 72.3% and 68.4%, respectively. Conclusions: SRT is safe and promising as a radical treatment for operable stage I NSCLC. The survival rate of SRT is potentially comparable to that of surgery. No significant financial relationships to disclose.
Serving the clinician and the patient: three ways that quality clinical guidelines can build on expert consensus statements and systematic reviews
Authors: Clare L Ardern
Journal: British Journal of Sports Medicine (2016)

For the busy clinician, keeping up-to-date with the latest evidence is challenging.1 A ‘one-stop-shop’ document that summarises the management of a particular disease or health condition is attractive. This editorial provides tips on how to produce clinical guidelines for sports and exercise medicine.

BJSM places high value on systematic reviews as level 1 evidence and important guiding lights for sports and exercise medicine (62 systematic reviews were published in 2015). Since these usually ask a very specific question and typically consider one aspect of a health condition, one systematic review cannot answer all the questions that are relevant to the management of a health condition.

Clinical guidelines represent higher order thinking, whereas a systematic review is more restricted in context. The key difference is that guidelines translate a body of evidence into management options for a particular health condition. Not as a recipe; guidelines must be applied with sound clinical reasoning.2 Guidelines have the potential to help resolve clinical conundrums in sports and …
Single-Dose Oral Cholera Vaccine in Bangladesh
Authors: Andrew S Azman, Francisco J Luquero
Journal: New England Journal of Medicine (2016)

To the Editor: The reported 6-month efficacy of a single dose of oral cholera vaccine in Bangladesh (May 5 issue),1 although seemingly modest, may have profound implications for future use of the vaccine. One-year protection from two doses in India and Bangladesh did not differ significantly from these new results, a finding that suggests that short-term single-dose protection is similar.2,3 In cholera outbreaks, a rapid response is crucial, and protection from the first dose (direct and indirect) will drive the effect of reactive vaccination.4 These findings open the door to rapid provision of a first dose during epidemics, while . . .
Doxorubicin hydrochloride and cyclophosphamide followed by tamoxifen, versus the combination of gonadotropin-releasing hormone analog and tamoxifen, in the treatment of premenopausal endocrine-responsive node-negative breast cancer.
Authors: H. Kim, B. Sohn, S. Kim, J. Lee, S. Ahn
Journal: Journal of Clinical Oncology (2010)

e11090 Background: The objective of this study is to report our experience of gonadotropin-releasing hormone analog plus tamoxifen (GnRHa+T) or doxorubicin hydrochloride and cyclophosphamide (AC) followed by tamoxifen (AC->T) in premenopausal women with hormone response, node negative breast cancer. Methods: We retrospectively reviewed the records of 587 premenopausal women with hormone- responsive, node-negative breast cancer. Of these, 269 were treated with doxorubicin hydrochloride and cyclophosphamide (AC) followed by tamoxifen (AC->T), and 318 were treated with gonadotropin-releasing hormone analog plus tamoxifen (GnRHa+T). Results: At a median follow-up time of 49 months, 25 patients had relapsed and 6 patients had died. Of the 6 deaths, 3 were related to breast cancer. DFS and OS did not differ between the AC->T and GnRHa+T groups. There were no difference of time to recurrence and death between two groups. Type of recurrence did not differ between the two groups. GnRHa+T treatment had no effect on blood profile and did not cause the development of detrimental symptoms but decreased bone mineral density. Conclusions: GnRHa +T treatment can be an alternative treatment option in pre-menopausal women with endocrine-responsive, node- negative, breast cancer patients. No significant financial relationships to disclose.
A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition
Authors: Elizabeth A Traxler, Yu Yao, Yong-Dong Wang, Kaitly J Woodard, Ryo Kurita, Yukio Nakamura, Jim R Hughes, Ross C Hardison, Gerd A Blobel, Chunliang Li, Mitchell J Weiss
Journal: Nature Medicine (2016)
Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy
Authors: Emory R. McTyre, Adam G. Johnson, Jimmy Ruiz, Scott Isom, John T. Lucas, William H. Hinson, Kounosuke Watabe, Adrian W. Laxton, Stephen B. Tatter, Michael D. Chan
Journal: Neuro-Oncology (2016)

In this study we attempted to discern the factors predictive of neurologic death in patients with brain metastasis treated with upfront stereotactic radiosurgery (SRS) without whole brain radiation therapy (WBRT) while accounting for the competing risk of nonneurologic death. We performed a retrospective single-institution analysis of patients with brain metastasis treated with upfront SRS without WBRT. Competing risks analysis was performed to estimate the subdistribution hazard ratios (HRs) for neurologic and nonneurologic death for predictor variables of interest. Of 738 patients treated with upfront SRS alone, neurologic death occurred in 226 (30.6%), while nonneurologic death occurred in 309 (41.9%). Multivariate competing risks analysis identified an increased hazard of neurologic death associated with diagnosis-specific graded prognostic assessment (DS-GPA) ≤ 2 (P = .005), melanoma histology (P = .009), and increased number of brain metastases (P<.001), while there was a decreased hazard associated with higher SRS dose (P = .004). Targeted agents were associated with a decreased HR of neurologic death in the first 1.5 years (P = .04) but not afterwards. An increased hazard of nonneurologic death was seen with increasing age (P =.03), nonmelanoma histology (P<.001), presence of extracranial disease (P<.001), and progressive systemic disease (P =.004). Melanoma, DS-GPA, number of brain metastases, and SRS dose are predictive of neurologic death, while age, nonmelanoma histology, and more advanced systemic disease are predictive of nonneurologic death. Targeted agents appear to delay neurologic death.
CXCR7 Is Expressed in B Acute Lymphoblastic Leukemia (ALL) Cells and Mediates Their Transendothelial Migration.
Authors: Ali Jalili, Neeta Shirvaikar, Imran Mirza, Sara Ilnitsky, Mark Penfold, Thomas J Schall, Anna Janowska-Wieczorek
Journal: Blood (2008)
Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602.
Authors: S. M. Smith, N. Bartlett, J. L. Johnson, J. Lister, A. F. Cashen, S. Jung, H. Schöder, K. Egan, B. D. Cheson
Journal: Journal of Clinical Oncology (2010)

8039 Background: Relapsed HL patients (pts) ineligible for transplant or relapsed despite stem cell transplant have a poor prognosis and a median survival of approximately six months. Most are heavily pretreated and poorly tolerant of additional cytotoxic therapies. Targeted and non-cytotoxic therapies are needed. Galiximab is a primatized IgG1λ monoclonal antibody which binds with high affinity to CD80 (B7.1), and induces cross-linking of CD80 molecules and cell-death via ADCC. CD80 is an excellent target in HL with expression on the majority of Reed-Sternberg cells, while expression on normal tissues is limited to activated B-cells, antigen-presenting cells, and T-cells. Methods: CALGB 50602 is a phase II study of galiximab in relapsed HL after ≥ 2 prior regimens. Entry criteria included ANC ≥ 500/μ L and plts ≥ 50K/μ L. Galiximab dose was 500 mg/m2 weekly × 4 weeks followed by 500 mg/m2 q 4 weeks until progression or toxicity. The primary endpoint was response, with 4 responders in the first 21 pts required to proceed to the second stage. Samples for tissue microarray, PK, cytokine analysis, and FcR polymorphisms were collected. Results: Between 6/2008-1/2009, 30 pts with classical HL were accrued at 10 CALGB institutions. 15 males and 15 females had a median age of 36 yrs (range, 22-70) and a median of 3 (range, 1-7) prior regimens. 20 pts (74%) had prior RT and 23 pts (85%) had failed prior autologous and/or allogeneic stem cell transplant. 1 pt never started treatment. There was 1 CR and 1 PR, with ORR 6.9% (95% CI 0.9, 22.8%); both responders progressed at 7.5 and 3 mos, respectively. 24 pts came off treatment for PD. The median TTP was 1.6 months. Galiximab was well-tolerated, with grade 3 or 4 non-hematologic toxicities limited to hypophosphatemia (n=3), elevated SGOT/SGPT (n=2), and infection (n=2). Conclusions: Despite being well-tolerated, galiximab had minimal activity in heavily pretreated pts with relapsed HL. CALGB's prompt accrual of a rare population and rapid screening for activity supports the ongoing unmet clinical need for targeted and non-cytotoxic agents in relapsed HL. No significant financial relationships to disclose.
Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476).
Authors: Nicholas D. James, Matthew Robert Sydes, Noel W. Clarke, Malcolm David Mason, David P. Dearnaley, Melissa Ruth Spears, Alastair W S Ritchie, J. Martin Russell, Chris C. Parker, Cyrill A. Rentsch, Jan Wallace, Jim Barber, Anna Lydon, Mahesh K B Parmar
Journal: Journal of Clinical Oncology (2016)

162 Background: STAMPEDE is a randomised controlled trial using a multi-arm multi-stage design. It recruits men (pts) with high-risk locally advanced or metastatic prostate cancer (PCa) starting long-term hormone therapy (HT) for the first time. The trial initially assessed adding one or two of three treatment approaches to standard-of-care (SOC). We report comparative survival data for the two original comparisons that stopped accrual early at pre-planned lack-of-activity analysis based on failure-free survival (FFS): celecoxib (Cox) and celecoxib + zoledronic acid (Cox+ZA). Methods: SOC was HT for at least 2yrs; RT was encouraged for men with M0 disease. Stratified randomisation allocated pts 2:1:1 to SOC (control), SOC+Cox or SOC+Cox+ZA. Celecoxib (400mg) was given twice daily until 1yr. Zoledronic acid (4mg) was given for six 3-weekly cycles then 4-weekly until 2yrs. The primary outcome measure was death from any cause. This pre-planned analysis is triggered by analysis of the “original comparisons” that continued accrual through all activity stages. Analyses use Cox proportional hazards model and flexible parametric models, all adjusted for stratification factors. Results: 1,245 men were contemporaneously randomised to these 3 arms (Oct2005-Apr2011). Groups were well balanced: median age 65yrs; 61% metastatic, 14% N+/X M0, 25% N0M0; 94% newly-diagnosed; median PSA 66ng/ml. Median follow-up was 62m. Grade 3-5 adverse events were seen in 35% SOC, 32% SOC+Cox, 32% SOC+Cox+ZA. There were 295 control arm deaths (82% PCa); median survival 68m. The adjusted HR was 1.00 (95% CI 0.82-1.22; p=0.99; median OS 69m) for SOC+Cox vs SOC; and 0.86 (95%CI 0.70-1.06; p=0.16; median OS 74m) for SOC+Cox+ZA vs SOC. Pre-planned analyses in men with metastatic disease showed HR 0.78 (95%CI 0.62-0.99) for SOC+Cox+ZA vs SOC. Further data will be shown. Conclusions: These data show no survival advantage for the addition of celecoxib alone for men starting long-term HT for the 1 st time. However, the addition of celecoxib combined with ZA demonstrated a survival advantage for men with metastatic disease, in a pre-planned analysis, and requires further investigation. Clinical trial information: NCT00268476.
Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18FDG PET/CT in a Patient With Prostate Cancer
Authors: Aurore Goineau, Stéphane Supiot
Journal: Clinical Nuclear Medicine (2016)

Institut de Cancérologie de l'Ouest Paul Papin Angers, France [email protected] Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain France Received for publication February 4, 2016; revision accepted February 13, 2016. Conflicts of interest and sources of funding: none declared.
Compensating Physicians for Telephone Calls
Authors: P C Sorum
Journal: JAMA (1994)

PHYSICIANS should be compensated for the time they spend talking with patients by telephone. <h3>Probable Benefits</h3> The telephone is very useful for patients. They can speak to the office nurse or the physician and do so frequently. From 1976 through 1978, a large percentage of patient-physician encounters were by telephone: 19% of general practitioner encounters, 18% of family practitioner encounters, 28% of pediatrician encounters, 23% of general internist encounters, 20% of obstetrician/gynecologist encounters, and 12% of general surgeon encounters.<sup>1</sup>Moreover, information and advice obtained by telephone are usually free. Use of the telephone also benefits third-party payers. Contact with the nurse or physician can prevent visits to the emergency department or the physician's office. For example, the majority of after-hours callers to one family practice clinic reported that they would have gone straight to the emergency department if they had not been able to call.<sup>2</sup>The results are
Case 25-1966
Authors: Allan L. Friedlich, Benjamin Castleman
Journal: New England Journal of Medicine (1966)

Presentation of CaseA seventy-four-year-old woman was admitted to the hospital because of dyspnea.She was a confused and unreliable historian who had resided at a nursing home for the previous four years. Two weeks before admission anorexia developed, and she had the onset of a cough productive of small amounts of greenish sputum. Two years earlier she had been seen at another hospital after what she believed was a "heart attack." For an unknown interval she had taken a digitalis preparation and nitroglycerin tablets.She stated that she might have had a heart murmur in her youth. She denied . . .
A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease
Authors: Qixiong Zhang, Hui Tao, Yongyao Lin, Ying Hu, Huijie An, Dinglin Zhang, Shibin Feng, Houyuan Hu, Ruibing Wang, Xiaohui Li, Jianxiang Zhang
Journal: Biomaterials (2016)
Safety and efficacy of fistula closure by endoscopic suturing: a multi-center study
Authors: Saurabh Mukewar, Nitin Kumar, Marc Catalano, Christopher Thompson, Wasif Abidi, William Harmsen, Felicity Enders, Christopher Gostout
Journal: Endoscopy (2016)

Background and aim: Endoscopic closure of fistulas is desirable but remains a challenge, especially for gastrogastric fistulas. The aim of this study was to assess the success rate for the closure of gastrointestinal fistulas using an endoscopic suturing device. Patients and methods: Electronic records at three medical centers were reviewed to identify patients who underwent sutured fistula closure as recorded on a central database. Demographic details, clinical variables, and details of the endoscopic procedure were recorded. Results: A total of 56 patients (mean age 54 ± 12.7 years) underwent fistula closure. Gastrogastric fistulas were most common (n = 29; 51.8 %). Sixteen patients (28.6 %) had undergone previous failed attempts at closure. Immediate success was universal (n = 56; 100 %). Thirteen patients had persistent closure without any need for further therapies, while 17 underwent additional endoscopic procedures, with successful closure in 4 /17. Only one patient had abdominal pain requiring hospital admission. Conclusion: Sutured closure of fistulas in a single session is safe and can be expected, even in what are known to be challenging cases. Sequential closure for recurrences is sometimes successful in the longer term.
P0018 : Adenosine protects liver against oxidative stress damage in liver Ischemia/Reperfusion (I/R) injury
Authors: A. Veljkovic, G. Kocic, T. Cvetkovic, D. Sokolovic, M. Radojkovic, T. Jevtovic, B. Djordjevic, M. Despotovic
Journal: Journal of Hepatology (2015)
Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)
Authors: Xenofon Papanikolaou, Carolina Schinke, Sharmilan Thanendrarajan, Adam Rosenthal, Nathan Petty, Maurizio Zangari, Christoph Heuck, Frits van Rhee, Joshua Epstein, Shmuel Yaccoby, Gareth J Morgan, Faith E Davies, Bart Barlogie
Journal: Blood (2015)
Mer Receptor Tyrosine Kinase Is a Novel Therapeutic Target In Multiple Myeloma
Authors: Sandra Christoph, Silke Maag, Deborah DeRyckere, Douglas K. Graham, Stephen V Frye, H. Shelton Earp, Jing Liu, Chao Yang, Weihe Zhang, Xiaodong Wang, Ahmet H. Elmaagacli, Dietrich Beelen
Journal: Blood (2013)
The Hospice Movement
Authors: Sylvia A. Lack
Journal: JAMA (1979)

<h3>To the Editor.—</h3> The EDITORIAL "The Hospice Movement" by John P. Callan, MD (241:600, 1979), inThe Journaladdresses relevant issues but contains inaccuracies and reflects misconceptions. The hospice movement does not want "care of the dying... [to] be excluded from the mainstream of medicine." In fact, our ultimate goal is reincorporation of timeless values and accepted methods into general medical care. Technologically specialized curative medicine has catalyzed the growth of hospice medical care as a natural balance. Part of our responsibility and commitment is to educate health professionals that a "care system" can coexist with the "cure system." This requires fundamental changes in attitude; to this end, the Hospice Education, Training, and Research Foundation has been incorporated in New Haven, Conn. Until these ultimate goals are realized, hospice care remains the only way to get competent and compassionate terminal medical care from a multidisciplinary team of paid and volunteer
Tumor-Specific TCR-Engineered Donor Lymphocyte Infusion Therapy with Reduced GvHD Induction Utilizing Novel Retrovirus Vector Silencing Endogenous TCR Expression
Authors: Hiroaki Ikeda, Hiroaki Ueno, Isao Tawara, Ayumi Kawamura, Naoko Imai, Sachiko Okamoto, Junichi Mineno, Kazutoh Takesako, Naoyuki Katayama, Hiroshi Shiku
Journal: Blood (2014)
Brucellosis in a refugee who migrated from Syria to Germany and lessons learnt, 2016
Authors: Roland Grunow, Daniela Jacob, Silke Klee, Dietmar Schlembach, Sabine Jackowski-Dohrmann, Vera Loenning-Baucke, Bettina Eberspächer, Sonja Swidsinski
Journal: Eurosurveillance (2016)

A teenage woman migrating from Syria arrived in May 2015 in Germany. She gave birth to a healthy child in early 2016, but became febrile shortly after delivery. Blood cultures revealed Brucella melitensis. In retrospect, she reported contact with sheep in Syria and recurrent pain in the hip joints over about five months before diagnosis of brucellosis. We discuss consequences for adequate treatment of mother and child as well as for clinical and laboratory management.
Genomic Landscape and Clonal Heterogeneity Underlying Progression and Relapse In Chronic Lymphocytic Leukemia (CLL)
Authors: Juhi Ojha, Jackline Ayres-Silva, Charla Secreto, Scott Van Wier, Susan L Slager, Rafael Fonseca, Tait D Shanafelt, Neil E. Kay, Esteban Braggio
Journal: Blood (2013)
The Disappearance of Sudden Infant Death Syndrome—Reply
Authors: Ernest Cutz
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Authors: N. Lawrence, A. Martin, G. Toner, M. Stockler, L. Buizen, D. Thomson, V. Gebski, M. Friedlander, A. Yeung, N. Wong, H. Gurney, M. Rosenthal, N. Singhal, G. Kichenadasse, S. Wong, C. Lewis, P. Vasey, P. Grimison
Journal: Annals of Oncology (2016)
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
Authors: J Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta, Marek Lommatzsch, Gary T Ferguson, William W Busse, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Viktoria Werkström, Magnus Aurivillius, Mitchell Goldman
Journal: The Lancet (2016)
Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.
Authors: Darrell J. White, Michael J. Kovacs, Andrew Belch, Keith Stewart, Christine Chen, Sheldon Rubin, David A. Macdonald, Erica Harnett, Judy-Anne W. Chapman, Lois E. Shepherd, Ralph M. Meyer
Journal: Blood (2007)